1 Reason Every Investor Should Know About AbbVie (ABBV)

AbbVie has delivered significant shareholder value, tripling its dividend payout and achieving a 494% total return over the past decade, largely due to its robust patent defense strategies. Despite the U.S. patent expiry of its former lead drug, Humira, in 2023, the company successfully navigated this challenge by rapidly scaling new treatments like Skyrizi and Rinvoq, which generated $7.8 billion and $3.7 billion respectively in H1 2025, leading to an 8% increase in total first-half revenue. This strategic transition and proven ability to extend drug exclusivity suggest a pathway for continued strong performance and dividend growth.

Analysis

AbbVie is demonstrating a successful transition beyond the 2023 U.S. patent expiration of its former lead drug, Humira. Despite Humira sales contracting by more than half, the company achieved an 8% increase in total revenue for the first half of 2025, underscoring the strength of its new product portfolio. This growth is primarily driven by the rapid adoption of its newer immunology assets, Skyrizi and Rinvoq, which launched in 2019. Skyrizi's sales surged 69% year-over-year to $7.8 billion in H1 2025, while Rinvoq generated $3.7 billion in the same period, collectively more than offsetting the decline in Humira revenue. The company's historical ability to prolong drug exclusivity through complex patent strategies, which contributed to a 494% total return over the past decade, provides a potential blueprint for extending the commercial life of these new injectable treatments. This operational success supports AbbVie's strong capital return profile, highlighted by a 221.6% dividend increase over the last decade and a current yield of 3.1%.

Key Decisions for Investors

• Given the demonstrated successful revenue transition away from Humira and the robust 3.1% dividend yield, investors may view AbbVie as a core holding for income and growth-oriented portfolios.
• Investor focus should be on the continued sales momentum of Skyrizi and Rinvoq, as their performance is now the critical determinant of the company's near-to-medium-term earnings growth.
• It is critical to monitor for any news or legal challenges related to the patent protection for Skyrizi and Rinvoq, as the company's ability to replicate its past success in extending exclusivity is key to the long-term investment thesis.